Interferon-β (IFN-β) treatment reduces the frequency of major MS attacks by 33% [3], and has been used to prevent exacerbation of relapsing-remitting MS (RRMS), including optic-spinal MS (OSMS) in Japan [4]. This evidence concerns the gene IFNB1 and myeloid sarcoma.